LIBLICENSE-L Archives

LibLicense-L Discussion Forum

LIBLICENSE-L@LISTSERV.CRL.EDU

Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
From:
LIBLICENSE <[log in to unmask]>
Reply To:
LibLicense-L Discussion Forum <[log in to unmask]>
Date:
Thu, 1 Aug 2013 20:14:04 -0400
Content-Type:
text/plain
Parts/Attachments:
text/plain (20 lines)
From: Rick Anderson <[log in to unmask]>
Date: Wed, 31 Jul 2013 22:03:21 +0000

>Elsevier is an appropriate comparison. Look at the price of American
>Journal of Kidney Disease from 2008 to 2009. Elsevier took over
>publication that year from the National Kidney Foundation. Our price
>for the journal increased 450%.

Fair point, but it's also true that you're describing a very different
situation: AJKD's price went up when Elsevier acquired it, but what Chuck
described is a sudden increase in a longstanding APS product.

I'm not defending Elsevier here, just pointing out the difference between
the two scenarios.

Rick Anderson
Interim Dean, J. Willard Marriott Library
University of Utah
[log in to unmask]

ATOM RSS1 RSS2